Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aleix Prat

Showing results (81-90 of 326) with videos related to

Pageof 33
Sort By:
Nature Reviews. Disease Primers|May 9, 2020
Immune-related adverse events of checkpoint inhibitorsManuel Ramos-Casals, Julie R Brahmer, Margaret K Callahan, et al.
Stem Cell Reports|June 18, 2014
Cell-state transitions regulated by SLUG are critical for tissue regeneration and tumor initiationSarah Phillips, Aleix Prat, Maja Sedic, et al.
Cancer Treatment Reviews|May 21, 2024
The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast CancerLuca Boscolo Bielo, Dario Trapani, Eleonora Nicolò, et al.
The Oncologist|January 26, 2019
Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2Aleix Prat, Jan Christoph Brase, Yuan Cheng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2012
Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancerAleix Prat, Maggie Chon U Cheang, Miguel Martín, et al.
Frontiers in Oncology|November 25, 2022
Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive/HER2-negative metastatic breast cancer with visceral crisis: A case reportFrancesco Schettini, Elia Seguí, Benedetta Conte, et al.
Cancer Research|October 24, 2014
Differentiation and loss of malignant character of spontaneous pulmonary metastases in patient-derived breast cancer modelsJessica Bockhorn, Aleix Prat, Ya-Fang Chang, et al.
NPJ Breast Cancer|February 13, 2021
Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®Richard Buus, Zsolt Szijgyarto, Eugene F Schuster, et al.
European Journal of Cancer (Oxford, England : 1990)|June 28, 2021
Erratum to 'Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis' [Eur J Cancer 149 (2021) 134-152]Francesco Schettini, Fabiola Giudici, Ottavia Bernocchi, et al.
NPJ Breast Cancer|November 26, 2025
Real-world outcomes of early-stage HER2-positive breast cancer patients treated with adjuvant paclitaxel and trastuzumabGiorgio Bonomi, Gaia Griguolo, Tommaso Giarratano, et al.
Pageof 33

Showing results (81-90 of 326) with videos related to

Sort By:
Pageof 33
Nature Reviews. Disease Primers|May 9, 2020
Immune-related adverse events of checkpoint inhibitorsManuel Ramos-Casals, Julie R Brahmer, Margaret K Callahan, et al.
Stem Cell Reports|June 18, 2014
Cell-state transitions regulated by SLUG are critical for tissue regeneration and tumor initiationSarah Phillips, Aleix Prat, Maja Sedic, et al.
Cancer Treatment Reviews|May 21, 2024
The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast CancerLuca Boscolo Bielo, Dario Trapani, Eleonora Nicolò, et al.
The Oncologist|January 26, 2019
Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2Aleix Prat, Jan Christoph Brase, Yuan Cheng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2012
Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancerAleix Prat, Maggie Chon U Cheang, Miguel Martín, et al.
Frontiers in Oncology|November 25, 2022
Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive/HER2-negative metastatic breast cancer with visceral crisis: A case reportFrancesco Schettini, Elia Seguí, Benedetta Conte, et al.
Cancer Research|October 24, 2014
Differentiation and loss of malignant character of spontaneous pulmonary metastases in patient-derived breast cancer modelsJessica Bockhorn, Aleix Prat, Ya-Fang Chang, et al.
NPJ Breast Cancer|February 13, 2021
Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®Richard Buus, Zsolt Szijgyarto, Eugene F Schuster, et al.
European Journal of Cancer (Oxford, England : 1990)|June 28, 2021
Erratum to 'Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis' [Eur J Cancer 149 (2021) 134-152]Francesco Schettini, Fabiola Giudici, Ottavia Bernocchi, et al.
NPJ Breast Cancer|November 26, 2025
Real-world outcomes of early-stage HER2-positive breast cancer patients treated with adjuvant paclitaxel and trastuzumabGiorgio Bonomi, Gaia Griguolo, Tommaso Giarratano, et al.
Pageof 33